viral pneumonia without influenza
Conditions
Interventions
Treatment Group:Conventional treatment + nebulized IFN-a1b
Control group:Conventional treatment + nebulized placebo
Sponsors
Beijing Ditan Hospital Capital Medical University
Eligibility
Sex/Gender
All
Age
14 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Patients of community-acquired pneumoniaage ,14-70. Gender does not limit. 2.Meet the clinical-defined virus pneumonia criteria: 1)fever(oral temperature=38.0?, or axillary temperature =37.4?, or prior history of fever within 48h. 2) with or without dyspenia 3) Chest radiogram manifestation: unilateral or bilateral chest radiogram test showed multiple (at least two lesions) or diffuse distribution of patchy or glass attenuation infiltrates (with or without consolidation) 3.Etiological examination confirm virus infection exclude influenza virus 4.Onset time=5d 5.Patients are able to accept nebulized inhalation treatment 6.Willing and able to provide written informed consent
Exclusion criteria
Exclusion criteria: 1. Clear laboratory evidence of Streptococcus ,Legionella pneumophila, Mycoplasma and Chlamydia infection; 2. Clear laboratory and clinical evidence of bacterial infection. e.g. PCT>1ug/L; 3. Use antiviral drugs within 1 week, and will use anther antiviral drug during the course of the disease; 4. Patients of sever pneumonia; 5. Current or prior hisrtory of critical lung basic diseases: pulmonary tuberculosis, lung cancer, pulmonary edema, atelectasis, pulmonary embolism, pulmonary eosinophilic infiltration and pulmonary vasculitis; 6. Severe hepatic and renal function with significant abnormalities: (1) AST, ALT is over 10 times more than the upper limits of normal; (2) serum creatinine is over 1.5 times more than the upper limits of normal; 7. Particpating another clinical studies within 30 days; 8. Allergic history of interferonor contraindication to interferon: angina, myocardial infarction and other serious cardiovascular disease; history of epilepsy or other central nervous system diseases; obvious abnormal hematopoietic system (platelet <30*10^9/L, the neutral granular cell <0.5*10^9/L); 9. Pregnant or nursing; 10. The survival time maybe less than 48 hours from screening; 11. Those subjects are not suitable for this study by investigator's judgement.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Alleviate symptoms of pneumonia; | — |
Secondary
| Measure | Time frame |
|---|---|
| Hospitalization time;Incidence of secondary bacterial pneumonia and antibiotic application;Viral quantity of throat swab; | — |
Countries
China
Contacts
Public ContactLi Xing Wang
Outcome results
None listed